Affiliation:
1. Department of Radiology, Massachusetts General Hospital, Boston 02114.
Abstract
The distribution of fluconazole in tissue of human volunteers was determined by positron emission tomographic scanning over a 2-h period following the infusion of a tracer dose of 18F-fluconazole (5 to 7 mCi) plus 400 mg of unlabeled drug (the standard daily dose of fluconazole). Previous studies have validated this approach for animals. From serial positron emission tomographic imaging and blood sampling, pharmacokinetics of fluconazole in tissue were determined. There was significant distribution of the radiolabeled drug in all organs studied, with nearly constant levels achieved by 1 h. Plateau concentrations of fluconazole in key organs (micrograms per gram) included the following: whole brain, 4.92 +/- 0.17; heart, 6.98 +/- 0.20; lung, 7.81 +/- 0.46; liver, 12.94 +/- 0.24; spleen, 22.96 +/- 2.5; kidney, 11.23 +/- 0.61; prostate, 8.24 +/- 0.58; and blood, 3.76 +/- 0.30. Since levels of fluconazole of > 6 micrograms/g are needed to treat infection with most strains of Candida and levels of > 10 micrograms/g are needed for Cryptococcus neoformans, Coccidioides immitis, and Histoplasma capsulatum, the following predictions can be made. The current standard dose of 400 mg/day should be more than adequate in the treatment of urinary tract and hepatosplenic candidiasis but problematic in the treatment of candidal osteomyelitis, even with the higher levels that develop after multiple doses. Similarly, higher doses should be considered, particularly in immunocompromised patients, with infection with C. neoformans, H. capsulatum, and C. immitis that involves the central nervous and musculoskeletal systems.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference38 articles.
1. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy;Anaissie E.;Am. J. Med.,1991
2. Fluconazole penetration into cerebral spinal fluid: implications for treatment of infections of the central nervous system;Arndt C. A.;J. Infect. Dis.,1988
3. Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS;Berry A. J.;Antimicrob. Agents Chemother.,1992
4. Pharmacokinetics and tissue penetration of fluconazole in humans;Brammer K. W.;Rev. Infect. Dis.,1990
5. Brammer K. W. and M. H. Tarbit. 1987. A review of the pharmacokinetics of fluconazole (UK-49 858) in laboratory animals and humans p. 141-150. In R. A. Fromiling (ed.) Recent trends in the discovery development and evaluation of antifungal agents. J. R. Prous Science Publishers S. A. Barcelona Spain.
Cited by
96 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献